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Purpose
GD2 is highly expressed in neuroblastoma (NB) and spe-
cifically recognized by antibodies ch14.18. Immunother-
apy with bolus infusion of ch14.18 in combination with
cytokines prolonged survival in patients at risk for relapse
but was associated with substantial toxicity, in particular
severe pain, requiring i.v. morphine [EJM 2010]. In an
attempt to reduce the pain side effect associated with
anti-GD2 therapy and to optimize antibody exposure, we
piloted a treatment using continuous infusion of ch14.18
produced in CHO cells (APN311) and report first results.
Materials and methods
Relapsed or refractory NB patients received 5 cycles of
6x106 IU/m2 s.c. IL-2 (d1-5; 8-12), 10 day continuous infu-
sion of 100 mg/m2 APN311 (d8-17) and 160 mg/m2 oral
13-cis-RA (d19-32). The cytolytic potential of antibody
treatment was assessed using a whole blood test (WBT)
and by CDC. For WBT, fresh heparinized whole blood of
patients was used as effector for lysis of 51Cr-labeled
human GD2+ LAN1 NB cells. Antibody specificity of lysis
was determined by adding excess of an anti-idiotypic anti-
body to APN311 (ganglidiomab). APN311 levels in sera
were determined by ELISA using ganglidiomab. Pain
assessment during APN311 infusions was done by stan-
dardized evaluation methods and by reduction/complete
avoidance of i.v. morphine. Clinical responses were
assessed in particular by MIBG scintigraphy.
Results
All analyzed patients demonstrated GD2 specific lysis in
their blood and serum against LAN1 NB cells. This lytic
activity was consistently high during all long term anti-
body infusions. In > 70% of patients the lytic activity of
whole blood in later cycles remained significantly above
base line until start of the next antibody infusion, thereby
creating a continuous lytic potential for several months.
Pain assessment showed that 80% of patients after 5 days
antibody infusion already in cycle 1 did not require i.v.
morphine anymore, and in later cycles there was almost
no need for i.v. morphine. Clinical response rates > 30%
based on MIBG evaluation were seen.
Conclusion
5 cycles of a 10 day continuous infusion of APN311 (in
conjunction with s.c. IL2 and oral 13-cis-RA) in relapsed/
refractory NB patients revealed a high and sustained
APN311-specific lytic potential against GD2+ NB cells in
whole blood. The pain side effect was substantially
reduced, thereby almost completely avoiding i.v. morphine
co-medication. Response rates of > 30% were observed
suggesting clinical activity of this novel treatment modal-
ity. Confirmatory clinical trials are warranted to substanti-
ate these first results.
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